ADXN addextherapeutics.com: Nilai bisnis marang pendapatan

Addex Therapeutics (ADXN) is scaling the creation of allosteric modulators through B2B partnerships to capture the neuropharmaceutical segment. This EV/Sales multiple chart demonstrates the ratio of capitalization to debt-free revenue, where 27500.00 forms the current metric value. Addex Therapeutics is developing precision drugs for dystonia and Parkinson's disease. A steady influx of patients in the EU and strict FDA/EMA regulations define the development of this ecosystem.
Rincian metrik keuangan lan pasar Addex Therapeutics Ltd. (ADXN)

For a comparative asset analysis, the investor utilizes EV/Sales, which compares the total enterprise value to sales volume, excluding the impact of debt load to identify the actual premium paid for revenue. In the case of Addex Therapeutics (ADXN), the trend of the company's value relative to revenue reflects expectations for future allosteric modulators, as current research revenues do not yet align with the potential of maturing pharma partnerships.